<DOC>
	<DOCNO>NCT01692132</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness prucalopride treatment Filipino patient chronic constipation prior laxatives fail provide adequate relief .</brief_summary>
	<brief_title>A Post Marketing Surveillance Study Safety Effectiveness Prucalopride Treatment Chronic Constipation</brief_title>
	<detailed_description>This 12-week open label ( people know identity intervention ) , multi-center , prospective ( patient identify follow forward time outcome study ) observational study assess safety effectiveness prucalopride among Filipino patient chronic constipation . Chronic constipation condition bowel movement infrequent incomplete prolonged time . The use prucalopride use accordance approve product label follow normal medical practice investigator . Patients take 2 mg prucalopride tablet orally daily . For elderly patient ( &gt; 65 year old ) , patient renal impairment require dialysis patient severe hepatic impairment , 1mg prucalopride daily give . Patients ask fill-up patient diary daily 12-weeks monitor bowel movement study period . All adverse event concomitant medication take patient study document accordingly . Patients monitor 12-week period observation patient prucalopride treatment .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Diagnosis chronic constipation history physical examination , include rectal exam History chronic constipation satisfy laxative Patient report , average , 2 few spontaneous bowel movement ( SBMs ) per week 1 follow last three month : hard ( little ball ) and/or hard stool 25 % bowel movement ( BMs ) ; sensation incomplete evacuation 25 % BMs ; strain defecation 25 % BMs ; sensation anorectal obstruction blockade 25 % BMs ; need digital manipulation facilitate evacuation 25 % BMs Females childbearing potential agree use highly effective contraceptive method Renal impairment require dialysis Secondary chronic constipation organic gastrointestinal ( GI ) disorder Intestinal perforation / obstruction due structural functional disorder gut wall , obstructive ileus , severe inflammatory condition intestinal tract Crohn 's disease , ulcerative colitis , toxic megacolon / rectum Hypersensitive Prucalopride components Patients receive concomitant drug know cause QTc prolongation Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Chronic Constipation</keyword>
	<keyword>Prucalopride</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>